Heyuan Bio

OBiO Technology (Heyuan Bio) is a leading Chinese contract development and manufacturing organization (CDMO) specializing in the gene and cell therapy (GCT) industry. Established in 2013 and headquartered in Shanghai, the company provides comprehensive end-to-end solutions spanning vector discovery, process development, and large-scale GMP manufacturing for viral vectors and cell products. Their expertise covers a wide array of modalities including adeno-associated virus (AAV), lentivirus, oncolytic viruses, and mRNA. OBiO operates state-of-the-art facilities designed to support global clinical trials and commercial-stage production for biotechnology and pharmaceutical partners. Publicly traded on the Shanghai Stock Exchange, the company is a key player in the global GCT supply chain, leveraging advanced technology platforms to accelerate the development of innovative therapies.